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ABSTRACT
Multiple studies have described extracellular microRNAs (ex-miRNAs) as being remarkably stable despite
the hostile extracellular environment, when stored at 4ºC or lower. Here we show that many ex-miRNAs
are rapidly degraded when incubated at 37ºC in the presence of serum (thereby simulating physiolo-
gically relevant conditions). Stability varied widely between miRNAs, with half-lives ranging from
~1.5 hours to more than 13 hours. Notably, ex-miRNA half-lives calculated in two different biofluids
(murine serum and C2C12 mouse myotube conditioned medium) were highly similar, suggesting that
intrinsic sequence properties are a determining factor in miRNA stability. By contrast, ex-miRNAs
associated with extracellular vesicles (isolated by size exclusion chromatography) were highly stable.
The release of ex-miRNAs from C2C12 myotubes was measured over time, and mathematical modelling
revealed miRNA-specific release kinetics. While some ex-miRNAs reached the steady state in cell culture
medium within 24 hours, the extracellular level of miR-16 did not reach equilibrium, even after 3 days in
culture. These findings are indicative of miRNA-specific release and degradation kinetics with implica-
tions for the utility of ex-miRNAs as biomarkers, and for the potential of ex-miRNAs to transfer gene
regulatory information between cells.
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Extracellular microRNAs (ex-miRNAs) are present in a wide
variety of biofluids, including serum, plasma, urine, cerebral
spinal fluid, saliva, tears, milk, and seminal fluid [1]. As such, ex-
miRNAs have been investigated as minimally-invasive biomar-
kers for a range of physiological and pathophysiological states
including tissue damage [2], cancer [3–5], infectious disease [6],
atherosclerosis [7], pregnancy [8], and diabetes [9]. In particular,
our group and others have investigated the utility of ex-miRNAs
in the context of the progressive muscle-wasting disorder
Duchenne muscular dystrophy (DMD) [10–17]. A set of highly
muscle-enriched miRNAs, the classical myomiRs (consisting of
the miR-1/206 family, MIPF0000038, and miR-133 family,
MIPF0000029 [18]) are elevated in the serum of DMD patients
and dystrophic animal models [10–17]. These myomiRs are
known to regulate myoblast proliferation and differentiation by
suppressing expression of stemness factors such as PAX3 and
PAX7, inhibiting DNA synthesis via POLA1, and promoting
MEF2 expression via the repression of HDAC4 [19–22]. miR-
206 in particular has been shown to play a key role in muscle
regeneration in vivo [23,24]. MyomiR release from dystrophic
muscle is associated with both degenerative [11,15] and regen-
erative [12–14,25] processes. Whether or not these ex-miRNAs
can act to transfer gene regulatory information between cells
remains an exciting area of ongoing research [26–28].
The concentration of miRNAs in the extracellular space is
necessarily a function of the rates of export, re-uptake, and
degradation. Several groups have commented on the remark-
able stability of ex-miRNAs at room temperature [3,29], in
frozen storage [30,31], and following multiple freeze-thaw
cycles [3,32,33]. Given that unmodified naked RNA oligonu-
cleotides are rapidly degraded (on the order of seconds) by
extracellular RNase activity if added directly to serum, or after
intravenous injection [3,34], the stability of ex-miRNAs was
somewhat surprising. The discovery of ex-miRNAs in biofluids
coincided with an explosion of interest in extracellular vesicles
(EVs) as both mediators of cell-to-cell signaling [35–40], and as
potential therapeutic delivery vehicles [41]. Indeed, encapsula-
tion of miRNAs within lipid vesicles (i.e. exosomes, microve-
sicles, and apoptotic bodies) would provide a simple and
elegant explanation for ex-miRNA stability in the hostile envir-
onment of the extracellular space [42]. However, while
miRNAs are certainly present within EVs [39], the vast major-
ity of ex-miRNA have been shown to be non-vesicular [43–47].
Consistent with these findings, we observed that ~99% of
extracellular miR-1, miR-133a and miR-206 were found to be
non-vesicular in dystrophic serum as determined by multiple
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orthogonal methodologies [13,14]. Furthermore, these
miRNAs were found to immunoprecipitate with AGO2 and
APOA1, indicating that they are likely stabilized in extracellu-
lar-ribonucleoprotein (ex-RNP) complexes [13].
Given that multiple groups have proposed that ex-miRNAs
can act as cell-to-cell signaling molecules, their stability under
physiological conditions is an unaddressed issue of high
importance. Here we have investigated the nuclease stability
of ex-miRNAs at 37°C in murine serum and cell culture
conditioned medium. We further utilized myotube cell cul-
tures to model ex-miRNA release kinetics. From these data we
have generated a mathematical model which describes the
behaviour of this system, and calculated decay/release rates
for each ex-miRNA tested. These findings have important
implications for the use of ex-miRNAs as biomarkers, and
for their functional relevance.
Results
Extracellular miRNAs in cell culture-conditioned medium
are degraded at different rates under physiological
conditions
To investigate the stability of ex-miRNAs, we sought to deter-
mine the half-lives of myomiRs (miR-1, miR-133a andmiR-206)
and non-myomiR controls (miR-16 and let-7a) at physiological
temperature (i.e. 37°C) in conditioned medium taken from
C2C12 myotube cultures. C2C12 cells are a mouse myoblast
cell line that differentiates into multinucleate myotubes in low
serum conditions (i.e. 2% horse serum, HS). C2C12 cells were
cultured in differentiation conditions for 6 days, so as to reach
a stage at which ex-myomiRs were being secreted into the cell
culture medium at high levels [14]. Cell culture medium was
then collected (72 hours after the previous change of the med-
ium) and incubated at 37°C to simulate human/mouse body
temperature. Aliquots of conditioned medium were removed
over a series of time points (i.e. 0, 1.5, 3, 6, 10, 24, 48, and
76 hours) and miRNA abundance determined by RT-qPCR.
Curves were fit to experimental data by non-linear regression
using a one phase exponential decay model. This experimental
design allows for the degradation rate to be measured in the
absence of further miRNA export or re-uptake.
In contrast with previous reports investigating ex-
miRNA stability in frozen storage or at room temperature
[3,29,31], we observed a progressive decline in all ex-
miRNA species analyzed after incubation under simulated
physiological conditions (Figure 1(a)). Strikingly, the ex-
miRNAs exhibited a wide range of stabilities. For example,
miR-1 and let-7a were rapidly degraded during the first
10 hours of incubation, as reflected in their short half-
lives (2.3 and 1.6 hours respectively). In contrast, miR-
133a was relatively stable over the course of the experiment,
with a calculated half-life of >13 hours. miR-206 and miR-
16 exhibited intermediate half-lives (7.2 and 9.6 hours
respectively) (Figure 1(b)). All ex-miRNAs reached plateaus
at a level 2–3 logs above the limit of quantitation (LOQ) for
each assay, indicating the presence of a nuclease-resistant
fraction for each measured ex-miRNA.
Figure 1. Extracellular miRNA stability at physiological temperature. (a) C2C12 myotube conditioned medium was incubated at 37ºC and miRNA abundance
determined at each time point by RT-qPCR. (b) Table of miRNA half-lives and goodness-of-fit (R2) values for each miRNA in C2C12 myotube conditioned medium. (c)
Serum from dystrophic mdx mice was incubated at 37ºC as indicated and miRNA abundance determined at each time point. (d) Table of miRNA half-lives and
goodness-of-fit (R2) values for each miRNA in dystrophic serum. Curves were fitted by non-linear regression using a one phase exponential decay model. Values are
mean±SEM, n = 2. LOQ, limit of quantification.
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Extracellular miRNAs in dystrophic serum are degraded at
different rates under physiological conditions
To determine whether the findings from the C2C12 myotube
cultures could be extended to the in vivo situation, we per-
formed an analogous experiment using serum samples col-
lected from dystrophin-deficient mdx mice (the most
commonly used mouse model of DMD). mdx mice undergo
a period of muscle degeneration and regeneration which is
reminiscent of the pathology observed in the muscles of DMD
patients [48]. Notably, myomiR levels are highly elevated
(50–100-fold relative to wild-type controls) in the serum of
mdx mice [10–12], and so mdx serum provides a useful model
in which to investigate ex-miRNA stability.
Frozen serum samples were thawed on ice, placed in a 37°
C incubator, and aliquots collected over a series of time points
(i.e. 0, 1.5, 3, 6, 10, 24, 48, and 76 hours). RNA was extracted
and miRNA levels determined as described above. An addi-
tional non-myomiR control miRNA, miR-223, was included
in the analysis. This granulocyte-specific miRNA has pre-
viously been used as an endogenous reference control for
data normalization by our group [12,49] and others [11,50].
Note that miR-223 is not expressed in C2C12 myotubes and
was therefore not analyzed in the cell culture studies described
above.
Remarkably, the patterns of miRNA degradation in mdx
serum were similar to those observed in C2C12 myotube
conditioned medium (Figure 1(c)). miR-1 was degraded at
the most rapid rate, decreasing by ~10-fold within the first
10 hours. miR-206 and miR-233 had intermediate half-life
values (~3 hours), and miR-133a and miR-16 degraded
more slowly (>11 and >8 hour half-lives respectively)
(Figure 1(d)). As with the results for C2C12 myotube condi-
tioned medium, levels of each ex-miRNA reached a plateau at
a level 1–3 logs over the assay LOQ values.
miRNA half-lives were highly correlated between mdx
serum and C2C12 myotubes conditioned supernatant
(Pearson r = 0.948, P = 0.014) indicative of similar degrada-
tion kinetics observed in biofluids of very different composi-
tions (Figure S1).
Extracellular miRNA stability is correlated with sequence
GC content
The observation that different miRNAs exhibit distinct stability
kinetics is surprising given that these miRNAs are assumed to be
protected from nuclease degradation in a similar manner (i.e.
through protein/lipoprotein complex formation). We therefore
reasoned that their stabilities might be determined by the intrin-
sic properties of the miRNA sequence itself. Notably, the miR-1
family miRNAs (miR-1 and miR-206) exhibited quite different
decay kinetics despite being closely-related. Inspection of the
sequences for these miRNAs revealed differences at four nucleo-
tide positions; one uridine and three adenosine base positions in
miR-1 are occupied by guanosine bases at the equivalent posi-
tions in miR-206 (Figure S2(a)). We therefore hypothesised that
the stability of a given ex-miRNA might be associated with its
GC content. Indeed, ex-miRNA half-life and GC content were
positively correlated (Pearson r = 0.918, P = 0.0277 for C2C12
myotube conditionedmedium and Pearson r = 0.824, P = 0.0438
for mdx serum) (Figure S2(b,c)).
Extracellular vesicle-associated miRNAs are stable
In the experiments described above, we observed that ex-
miRNA levels reached a plateau after incubation at 37°C
which was much higher than the calculated assay LOQs.
These findings suggest the existence of a sub-population
(comprising between 4% and 34% of the starting material)
of nuclease-resistant ex-miRNAs that remain stable, even after
incubation at 37°C for 3 days. One possibility is that such
miRNAs might reside within EVs which provide protection
from nuclease-mediated degradation [51]. We therefore
sought to assess miRNA stability in EVs incubated at 37°C.
EVs were isolated from C2C12 myotube conditioned med-
ium using a combination of ultra-filtration (using tangential
flow) and size exclusion liquid chromatography (UF-LC),
a methodology that we have previously developed in order to
generate concentrated, pure, and intact vesicles devoid of ex-
RNP contamination [52]. LC performance was monitored by
UV spectroscopy at 280 nm (Figure 2(a)). The high molecular
weight eluates (containing EVs) were collected, pooled, and
characterized. Nanoparticle tracking analysis showed a well-
defined peak with a modal size of 125 nm, consistent with the
expected size range for exosome-like EVs (Figure 2(b)).
Similarly, the known exosome markers; ALIX, TSG101, and
CD81 were readily detectable in the pooled EV fractions
(Figure 2(c)).
During EV purification by UF-LC, soluble extracellular
proteins (including RNAses) are separated from the vesicles.
Given that degradation of ex-miRNAs is mediated by extra-
cellular RNases [51], direct comparison of miRNA stability in
conditioned medium with purified EVs is potentially mislead-
ing. We therefore sought to reconstitute the hostile RNase-rich
extracellular environment by resuspending purified C2C12
myotube-derived EVs in PBS containing 2% HS in order to
mimic the biological composition of the neat conditioned
medium.
Concentrated EV preparations, and unfractionated condi-
tioned medium from the parent cultures, were placed at 37°C
and aliquots collected after 0, 1.5, 6, and 24 hours incubation.
RNA was extracted and miRNA abundance levels determined
by RT-qPCR. Three independent C2C12 myotube cultures
and EV isolations were performed on separate days for this
analysis. Results for conditioned medium samples were simi-
lar to those reported above (Figure 1(a)), whereby
a progressive decrease in miRNA levels was observed in all
cases (Figure 2(d)). Furthermore, the rate of decline was
different between miRNAs, with miR-1 and let-7a exhibiting
rapid decreases, while miR-133a and miR-16 had slower rates
of decline (Figure 2(d)). In contrast, miRNA levels in the EV
fractions were relatively stable. Initial small, but rapid,
decreases were observed in the first 1.5 hours for miR-1,
miR-206 and miR-16, which may represent miRNAs that are
associated with the outside surface of the EVs, or with the
carryover of vesicle-free ex-miRNA during EV purification,
and therefore not protected from extracellular RNase activity
(Figure 2(d)). EV-associated miR-206, miR-16 and let-7a
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reached early plateaus. Indeed, EV-associated let-7a showed
no reduction below the initial starting amount. The propor-
tions of ex-miRNAs that were contained in EVs were calcu-
lated to be ~2% for all miRNAs except for let-7a, which was
enriched in EVs to a greater extent (~10–30%) (Figure 2(e)).
These values are similar to our previous estimates for these
miRNAs [13,14]. Notably, let-7a has been previously reported
to be preferentially enriched in EVs derived from human
Figure 2. Stability of extracellular vesicle-associated miRNAs at physiological temperature. Extracellular vesicles (EVs) were isolated from C2C12 myotube conditioned
medium (CM) by tangential flow filtration and size exclusion liquid chromatography. (a) 280 nm absorbance trace for liquid chromatography fractions. The pooled
fractions which contain the EVs are indicated on the plot. Isolated EVs were analyzed by (b) nanoparticle tracking analysis, and (c) Western blot for exosome markers
(ALIX, TSG101, and CD81). (d) Isolated EV or unfractionated CM samples were incubated at 37ºC and miRNA abundance determined at each time point by RT-qPCR.
(e) Estimation of the proportion of ex-miRNAs that are unstable and non-vesicular (i.e. the amount of miRNA that is degraded after incubation at 37°C for 76 hours,
from Figure 1), EV-associated (i.e. the proportion of ex-miRNA contained in the EV fractions after liquid chromatography), and the stable non-vesicular (i.e. the
proportion of ex-miRNA remaining after incubation at 37°C for 76 hours minus the EV-associated fraction). Values are mean±SEM, n = 3.
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plasma [44], which may account for the discrepancy between
this miRNA and the others measured here. These data suggest
that ex-miRNAs contained within EVs are much more stable
than non-vesicular ex-miRNAs. However, the observation
that EV-associated miRNAs constitute the minority of the
total ex-miRNA pool means that these findings cannot fully
account for the nuclease-resistant fraction observed in the
plateau phase in Figure 1. These findings therefore imply the
existence of a further, non-vesicular subpopulation of ex-
miRNAs that is highly resistant to degradation at 37°C
(Figure 2(e)).
It has recently been suggested that ex-miRNAs present in
cell culture media supplements such as fetal bovine serum
(FBS) and HS can confound cell culture investigations of
extracellular RNA function [53]. All miRNAs investigated in
this study are completely conserved between human, mouse,
cow and horse, with the exception of miR-16, which exhibits
some minor differences at the 3ʹ terminus (Figure
S3(a)). As such, the murine miRNA TaqMan assays utilized
here are expected to also amplify homologous miRNAs from
cow and horse sera. To exclude the possibility that detection
of non-murine miRNAs is complicating our analysis, we
extracted RNA from undiluted HS and FBS and measured
miRNA levels by RT-qPCR. Importantly, these miRNAs were
generally detected at very low levels in HS (i.e. miR-1 was
mostly undetected, miR-133a Cq>36, miR-206 Cq>36, let-7a
Cq>34, and miR-16 Cq ~30) (Figure S3(b)). The very low
levels of the miRNAs-of-interest in these undiluted supple-
ments, and the fact that they were further diluted in the cell
culture medium by 6.67-fold and 50-fold for FBS (for growth
medium) and HS (for differentiation medium) respectively,
suggests that exogenous serum contaminants are unlikely to
have significantly affected the findings reported in this study.
Similarly, EVs isolated from an equivalent volume of HS
exhibited exosome-like particle sizes, but were not enriched
for murine exosome markers, and contained ex-myomiRs at
levels ~200-fold lower than in C2C12 myotube-derived EVs
(data not shown).
Release of extracellular miRNA from myotube cultures
Having found that secreted ex-miRNAs exhibit sequence-
dependent decay kinetics, we were further motivated to exam-
ine whether similar differences are observed in the rate of ex-
miRNA cellular release. To investigate the ex-miRNA release
kinetics in cell culture, C2C12 cells were first differentiated to
form myotubes. The culture medium was discarded, the cells
were washed with PBS in order to remove any residual ex-
miRNAs that may be bound to cells or the cell culture dish,
and then fresh differentiation medium was added.
Subsequently, conditioned medium was harvested at various
time points (0, 0.5, 1, 2, 3, 6, 10, 24, 48, and 72 hours) and ex-
miRNA abundance determined by RT-qPCR for miR-1, miR-
133a, miR-206, miR-16 and let-7a (Figure 3). This experiment
was designed to measure the changes in ex-miRNA levels in
cell culture supernatant which are a function of both release
and degradation.
Extracellular miRNA concentration was modelled using
non-linear regression as a function of three processes;
a rapid release (Release1, 1st order), degradation (1st order),
and a gradual release (Release2, 0th order). The rate constant
for miRNA decay (kdegradation) was determined empirically
from the experiments described above (Figure 1). The model
is described by Equation (1), where t is time and c is
a constant.
cdegradation process formedium, the C2C12 myotubes
rapidly released miRNAs. The concentration of ex-
miRNAs initially peaked between 0.5 and 1 hours (Figure
3(a-e)). The ex-miRNA levels subsequently dropped as
a consequence of the degradation process for all miRNAs,
except for miR-16. A second, more gradual release phase
was observed for miR-133a and miR-206 (Figure 3(b,c)).
For the miRNAs with the fastest rates of degradation (miR-
1 and let-7a) the Release2 component was negligible, likely
as a consequence of parity between the release and degra-
dation processes (Figure 3(a,e)). For these miRNAs, the
extracellular concentration remained stable after
~10 hours. In contrast with the other miRNAs, the extra-
cellular concentration of miR-16 increased above the levels
observed during the initial rapid release phase (Figure 3
(d)). Rate constants for the two release processes were
inferred using a combination of experimental data and
modelling (Figure 3(f)).
The release and degradation processes were simulated
using the model described in Equation (1) and rate constants
calculated above. Simulated data for two representative
miRNAs (miR-1 and miR-206) illustrate the differences
between these three processes (Figure 4(a,b)).
The simulated data for each miRNA is shown whereby each
component is plotted separately for Release1 (Figure 4(c)),
Release2 (Figure 4(d)) and Degradation (Figure 4(e)). For the
Release1 component, kinetics differed between miRNAs,
although the half-times were rapid (ranging from 0.07 to
0.7 hours, Figure 4(f)). Interestingly, miR-1 exhibited the long-
est Relase1 half-time, although there was no significant correla-
tion between ex-miRNA Release1 half-times and GC content in
this case (Figure 4(f)). In contrast, the Degradation and
Release2 components were strikingly different between
miRNAs (Figure 4(d,e)).
½miRNA ¼ krelease1:½initial
kdegradation  krelease1 :ðe
ðkrelease1:tÞ  ekdegradation :tÞ þ krelease2:t:c (1)
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Discussion
Here we have analyzed the stability and release kinetics of ex-
miRNAs at physiological temperature, in order to model the
likely behaviour of these molecules in biofluids in vivo. While
ex-miRNAs have been previously described as highly stable at
room temperature or when frozen, we observed that miRNAs
are progressively degraded when subjected to physiological
temperature. Surprisingly, miRNAs were found to exhibit
a wide range of stabilities, with half-lives in the range of
hours, and remarkably similar results were observed in both
myotube-conditioned cell culture medium and murine serum.
The investigation of ex-miRNA stability is important for
understanding absolute miRNA levels in biofluids. For exam-
ple, miR-133a was the most highly expressed myomiR in adult
mdx serum (Figure 1(c)). Given the low stability of miR-1
compared to miR-133a, one might hypothesise that miR-1
could be exported at similar rates as miR-133a in vivo, but
persists in the circulation for a shorter amount of time.
Figure 3. Analysis of extracellular miRNA release after cell culture medium change. ex-miRNA release was modelled using C2C12 myotube cultures. ex-miRNA levels
were determined by RT-qPCR in C2C12 myotube conditioned medium at the indicated time points after changing the medium at time zero for (a) miR-1, (b) miR-
133a, (c) miR-206, (d) miR-16, and (e) let-7a. Values are mean±SEM, n = 3. (f) Table of kinetic constants and model goodness-of-fit (R2) values for each miRNA.
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Similarly, differential ex-miRNA stability may account for
some of the discrepancies observed between intracellular and
extracellular miRNA levels [43]. Differences in ex-miRNA
stability may result in a ‘decoupling’ of the relationship
between miRNA tissue expression and biofluid abundance
which, when measured at the steady state, might erroneously
be considered evidence for selective secretion.
Previous investigations of ex-miRNA stability at room
temperature have reached different conclusions, with some
studies reporting that ex-miRNAs are relatively stable
Figure 4. Modelling of extracellular miRNA release kinetics. ex-miRNA release and degradation components were simulated based on a mathematical model fitted to
empirical data. The Degradation rate constants were determined using data from Figure 1. The Release1 and Release2 rate constants were determined using data
from Figure 3. The three processes contributing to steady-state ex-miRNA levels were plotted separately for two representative miRNAs; (a) miR-1, which exhibits
a negligible Release2 component, and (b) miR-206, which exhibits a prominent Release2 component. Simulated data for the three processes contributing to ex-
miRNA levels were modelled individually in order to compare miRNAs for (c) the first release process (Release1), (d) the second release process (Release2), and (e)
Degradation. Equations used to generate the curves are shown on the plots.
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[3,29,33], whereas a study by Köberle et al. reported the
opposite [51]. The latter study is notable as several of its
findings bear a striking resemblance to those reported here.
Specifically, that miRNAs are not stable, and that they are
degraded at different rates. Importantly, this study also
observed that miR-1 was the least stable, and that miR-16
decayed much more slowly [51], consistent with our findings.
The differences between these studies may be accounted for
by the limited number of miRNAs tested, the use of human
plasma [3], or the relatively short time period analyzed [33].
Notably, a study by Yang et al., showed that the small RNA
MIR2911 (initially described as a plant miRNA but later
shown to be a 26S ribosomal RNA fragment [54]) that is
highly stable in serum, is non-exosomal, and GC-rich [55].
While these observations resemble some of those reported in
the present study, this small RNA may constitute a unique
case. For example, in contrast with the myomiRs studied here
[13], serum MIR2911 is insensitive to proteinase
K treatment [55].
In contrast with myotube conditioned medium, we
observed that ex-miRNAs in isolated EVs were highly stable
(Figure 2). However, the majority of studies have shown that
ex-miRNAs in conditioned medium are predominantly non-
vesicular, suggesting that protection from RNase degradation
is primarily mediated by association with ex-RNPs (e.g.
Argonaute proteins such as AGO2, HDL components such
as APOA1, or other proteins such as NMP1 [13,43,44,47]). It
is likely that the various miRNA-binding proteins may pro-
vide different degrees of RNase protection.
ex-miRNA half-lives were correlated with GC content, such
that the most GC-rich miRNA investigated (miR-133a) was also
the most stable. Such a sequence-dependent relationship is sur-
prising, as it would suggest that Watson-Crick base pairing
might be involved in stabilizing a particular miRNA. However,
many RNA binding proteins interact with RNA substrates in
a sequence-independent manner. For example, AGO2 primarily
makes contact to the miRNA guide through hydrogen bonds
and salt bridges to the phosphodiester backbone, and van der
Waals interactions with the ribose sugars [56]. Such binding
therefore leaves the Watson-Crick face solvent exposed, such
that it is available for binding to a cognate target transcript. In
vitro studies of recombinant AGO2 suggest that miRNAs are
held tightly within the complex [57], and that binding to syn-
thetic complementary target molecules facilitates miRNA
unloading [57]. Furthermore, AGO2 exhibits a weaker binding
affinity for double-stranded RNA than for single-stranded RNA
[58]. It is therefore possible that binding to extracellular AGO2
accounts for the population of ex-miRNAs that are resistant to
nuclease degradation, even after incubation at 37°C for 3 days.
As such, the ex-miRNAs of the unstable population, which are
rapidly degraded at sequence-dependent rates, are likely to
reside within distinct ex-RNP complexes.
To date, relatively few studies have investigated the stabi-
lity of ex-miRNAs, and the majority of these have analyzed
RNA stability either at room temperature, or in frozen sto-
rage. These studies are important for determining how best to
store and handle biofluid samples for analysis of extracellular
nucleic acids and/or EVs, and are relevant to the potential
utility of miRNA biomarkers. The relative stability (or lack
thereof) of ex-miRNAs at physiological temperature is an
important factor in terms of their potential for biological
functionality. Rapid degradation may limit the capacity of
cell-to-cell communication over long distances. Instead, if
RNP-associated ex-miRNAs act as signaling molecules at all,
it will likely be in a ‘short range’, paracrine manner via the
interstitial space.
Several studies have reported EV-mediated miRNA trans-
fer between cells in the muscle niche [26–28,59], although the
use of sub-optimal methods of EV isolation (specifically,
polymer precipitation using commercial kits [60,61]) in
some of these studies limits their usefulness. Importantly,
vesicle-associated miRNAs constitute a tiny minority of the
total ex-miRNA pool, raising the obvious question as to what
the purpose (if any) of the remaining non-vesicular majority
is. Indeed, non-vesicular ex-miRNAs have been dismissed as
non-functional, cellular waste by some groups [42]. However,
asymmetric patterns of intra- and extracellular miRNA levels
are potentially indicative of a selective export mechanism, and
therefore a regulated process, at least in the case of some
miRNAs [43]. To date, there has been no clear demonstration
that ex-miRNA-RNP complexes are capable of being taken up
by recipient cells in order to induce gene silencing events [62].
Instead, ex-miRNA-RNP complexes may execute a function
distinct from their well-established roles in gene regulation.
All ex-miRNAs measured were rapidly released by differ-
entiated C2C12 myotubes within 30 minutes of replacing the
culture medium (Figure 3). These findings are similar to those
reported by Wang et al., whereby a sudden burst of miRNA
release was observed in human cancer cells immediately after
serum withdrawal [43]. The authors hypothesised that acute
serum withdrawal provides a stimulus for miRNA export [43].
However, in the results presented here, the serum concentra-
tion was the same both before and after changing the med-
ium, suggesting that the medium change alone (and not
necessarily serum withdrawal) is sufficient to induce
a similar rapid miRNA release response to that reported by
Wang et al., Notably, the ex-miRNA levels measured imme-
diately after changing the medium were much higher than
background, suggestive of a rapid, and active export mechan-
ism [43]. Alternatively, some miRNA carrier complexes might
be attached to the outside of the cell by weak interactions and
are subsequently liberated upon the addition of new medium.
The requirement for medium change is a potential limitation
of the current study as this may constitute an artificial stress
situation that is not representative of in vivo miRNA release.
Methodological improvements that allow for the biochemical
tracking of newly synthesised and exported miRNAs without
the need to change the culture medium will be required to
address this issue.
For non-linear regression of cellular release data (Figure 4),
kdegradation was constrained using experimentally determined
values from Figure 1(b). However, slightly better goodness-of-
fit (R2) values could be obtained by not constraining this rate
constant, suggesting that secreted factors may influence the rate
of ex-miRNA degradation (which are absent in the experiments
performed in serum or isolated myotube conditioned medium,
Figure 1). However, the measurement of ex-miRNA is inher-
ently prone to noise [32]. Such variation may result in minor
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differences between experiments which affect the R2 value for
each ex-miRNA model. Alternatively, there may be some re-
uptake of secreted miRNAs that manifests as a ‘degradation-
like process’ and which we did not take into account in our
model. Even so, the high R2 value for let-7a (0.92) suggests that
the model is sufficient to explain the majority of the experi-
mental data without the need for an additional re-uptake term
in this case.
In conclusion, our findings underline the importance of
considering degradation and release kinetics for understanding
steady-state ex-miRNA levels. A limitation of our study is the
relatively small number of miRNAs investigated (six for con-
ditioned medium and seven for murine serum). Future work
must focus on determining the universality of the results pre-
sented here, and investigate the mechanisms underlying these
observations. Taken together, these findings suggest that
changes in sample collection protocol can significantly influ-
ence ex-miRNA levels, even prior to sample processing and
storage. This must be taken into consideration when working
with ex-miRNA based biomarkers. The relative stability of ex-
miRNAs also has implications for their capacity to transfer
gene regulatory information between cells.
Materials and methods
Animal samples
Animal studies were conducted in accordance to procedures
approved by the UK home office (project licence 30/2907).
24 week old female dystrophic mdx mice (C57BL/10ScSn-
Dmdmdx/J) were sacrificed by escalating CO2 concentration
and blood was collected immediately post mortem from the
jugular vein using Microvette CB300 capillary serum collec-
tion tubes (Sarstedt, Leicester, UK). Samples were incubated
on ice for 1 hour to allow samples to clot and then centrifuged
at 10,000 g for 5 minutes to pellet cellular blood. The super-
natant was carefully removed and transferred to fresh tubes
and stored at −80°C. No samples were visibly hemolyzed.
Cell culture
C2C12 cells were maintained in growth medium (GM;
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 15% FBS) and 1% antibiotics/antimycotics (all Life
Technologies) at 37°C with 5% CO2 and switched to differ-
entiation medium (DM; DMEM supplemented with 2% HS)
for 6 days in order to induce the formation of multinucleate
myotubes. Cell culture-conditioned medium was centrifuged
at 2,000 g for 5 minutes at 4°C, and then passed through
a 0.22 µm filter to ensure the removal of any residual cells
or debris that may have been carried over. Filtered condi-
tioned medium was stored at −80°C.
miRNA RT-qPCR
Cell culture conditionedmedium or serumwas incubated at 37°C
to simulate physiological temperature and aliquots (25 µl for
serum or 300 µl for cell culture conditioned medium) removed
at time points as indicated. Liquid samples were immediately
placed in TRIzol LS (Thermo Fisher Scientific) in order to prevent
further RNA degradation. An external spike-in control oligonu-
cleotide (3 µl of 5 nM stock) corresponding to the non-
mammalian miRNA; cel-miR-39 (5′-UCACCGGGUGUAAAUC
AGCUUG-3ʹ, IDT, Leuven, Belgium), was added to the TRIzol
LS/liquid mixture to enable miRNA normalization between sam-
ples collected at the different time points [49]. RNAwas extracted
after collection of all samples.
RT-qPCR studies were designed to conform to community
standards (the MIQE guidelines [63]) where appropriate or
possible. Our methods for miRNA detection and quantifica-
tion have previously been described in detail [49,64]. Briefly,
cDNA synthesis was performed using the MicroRNA Reverse
Transcription Kit (Life Technologies) and appropriate
miRNA-specific hairpin RT primers in multiplex format.
Subsequently, miRNAs were amplified using Small RNA
TaqMan assays and TaqMan Gene Expression Master Mix
on a Step-One Real-Time PCR instrument (all Thermo
Fisher Scientific) as according to manufacturer’s instructions.
miRNA assay product IDs are shown in Table S1. Universal
cycling conditions were used; 10 minutes at 95ºC, followed by
40 cycles of 95ºC for 10 seconds and 60ºC for 1 minute.
For absolute quantification, sample miRNA quantities were
compared to a 10-fold dilution series of synthetic miRNA
oligonucleotides (IDT) that were reverse transcribed and
amplified in parallel to experimental samples. Absolute quan-
tification of the external spike was used to correct for differ-
ences in extraction efficiencies between samples. The cel-miR
-39 copies per sample were divided by the mean of all cel-miR
-39 measurements to generate a scale factor (such that the
mean of all scale factors was equal to one). miRNA-of-interest
copies where then divided by the scale factor for each sample
in order to normalize the data while preserving the natural
range of copy number values. To obtain serum miRNA con-
centrations (copy numbers per milliliter biofluid), the ratio of
input volume used for extraction, resuspension of RNA,
reverse transcription and PCR was calculated and the normal-
ized miRNA copy number values scaled accordingly. We have
previously observed that all miRNA TaqMan assays are linear
down to 300 copies per PCR reaction (although lower con-
centrations were not tested) [14]. For the purposes of this
study we defined the LOQ as this value (i.e. 300) multiplied by
the same scaling factor described above (to convert the LOQ
to copies per ml of biofluid).
Relative quantification was performed using the Pfaffl
method [65]. PCR reaction efficiencies were determined
empirically using LinRegPCR [66].
EV isolation
C2C12 cells were seeded in ten 150 mm plates in GM, medium
was switched to DM for six days to induce myogenic differentia-
tion and conditioned medium was collected (two days after the
last medium change). Extracellular vesicles were isolated from
differentiated C2C12 myotube conditioned medium by size-
exclusion liquid chromatography (SEC-LC) as described pre-
viously [52]. Briefly, debris from the crude conditioned medium
samples was removed by centrifugation at 300 g for five minutes,
followed by 2,000 g for ten minutes in fresh tubes. Samples were
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passed through 0.22 µm filters and then run through a 10 kDa
tangential flow membrane to concentrate the sample to ~15 ml
volume, followed by a further filtration step using 10 kDa spin
filters (Sartorius, Goettingen, Germany) (centrifugation at
4,000 g for 15 minutes at 4°C) to further concentrate the sample
to a volume less than 2 ml. Concentrated samples were injected
into a Sephacryl column containing Sepharose 4 Fast Flow resin
(GE Healthcare, Little Chalfont, UK) and linked to an ÄKTA
pure system with UV flow cell (GE Healthcare) for size-
exclusion fractionation. Fractions were collected based on UV
absorbance (protein content) and the EV-containing fractions
(numbers five to eight) were pooled and further concentrated to
a volume of ~200 µl using a 10 kDa spin filter (MilliporeSigma).
Nanoparticle tracking analysis
Nanoparticle tracking analysis was performed using the
NanoSight NS500 instrument and NTA 3.1 analytical software
(both Malvern Instruments, Malvern, UK). Samples were
diluted 1:500 in PBS to achieve a particle count of between
2 × 108 and 2 × 109 particles per ml. Three 30 second videos
for each sample were recorded and analyzed using the script
and batch control facilities.
Western blot
EV sample total protein concentrations were determined by
BCA assay (Thermo Fisher Scientific, Loughborough, UK),
and 10 µg of protein separated by SDS-PAGE using
NuPAGE Sample Reducing Agent and precast NuPAGE
4–12% Bis-Tris Protein Gels (both Thermo Fisher
Scientific). Precision Plus Protein Dual Color Standards lad-
der was utilized to determine the size of protein bands (Bio-
Rad Laboratories, Perth, UK). Proteins were transferred to
a polyvinylidene difluoride (PVDF) membrane and probed
with antibodies as appropriate (details of primary and sec-
ondary antibodies are provided in Table S2).
Chemiluminescence was measured using the Odyssey Fc
Imaging System (LI-COR Biosciences, Cambridge, USA).
Statistical analysis
Correlation analysis, linear regression, and non-linear regres-
sion were performed using GraphPad Prism 5 (GraphPad
Software Inc, La Jolla, CA).
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